Articles on

The US 5-year yield is up 22 bps this month to its highest since February 2020 on inflation tailwinds and rate hike expectations, states Bill Baruch of Blue Line Futures.
US equities had a slight downward bias overnight as market participants await this week’s earnings reports, states Ian Murphy of
The broad stock market has strongly reversed upward at the end of last week, says Larry McMillan of Option Strategist.
US and world indices start the week well off Friday's highs, following a strong US retail sales release, which highlighted the old saying “never underestimate the spending power of Americans,” except for inflation, says Adam Button of
The wild rotation that has been a hallmark of 2021 has returned, with money racing into cyclical areas; we’re still sticking with a stock-by-stock approach — such as these energy ideas, explains Mike Cintolo, growth stock specialist and editor of Cabot Top Ten Trader.
Great Bear Resources (Vancouver: GBR) (OTC: GTBAF) — and its shareholders — benefited from the combination of an analyst site visit and a great news release in quick succession, notes Brien Lundin, mining sector specialist and editor of Gold Newsletter.
Back in 2005, Merck (MRK) was largely written off, with slowing innovation and a legal battle over Vioxx, one of its biggest drugs, suggests Genia Turanova, editor of Curzio Research's Unlimited Income.
The shares of BlackBerry Ltd. (BB) surged after the company announced multiple new partnerships over the last few days, observes Fernanda Horner, an analyst with Bernie Schaeffer's advisory newsletter, Schaeffer's Investment Research.
One day after the Federal Reserve signaled a slow-and-steady approach to tapering fixed-income asset purchases, it was up and away for the S&P 500 (SPX), says Jon Markman, growth-stock specialist and editor of Strategic Advantage.
It’s never a bad idea to know how to minimize your equity exposure, especially right now, as the market is showing some cracks in its armor lately, says Jay Soloff of Investors Alley.

Virtual Learning

Millions of people are experiencing the devastating, often long-term effects of mTBI (mild traumatic brain injury) and PTSD (post-traumatic stress disorder), with few, if any, effective treatments available. Lobe Sciences' goal is to change that fact, and during this presentation, Philip Young, CEO and director, will outline a path for the development of therapeutics for which the company intends to seek FDA approval in the United States, and similar approvals internationally.
Learn about the Crush Capital private placement. Crush Capital is the creator of Going Public®, a new original series where viewers can click-to-invest in featured deals while they watch.
<p>Most people believe top options traders have crazy high IQ. But not according to Warren Buffet. In fact, he said: "Investing is not a game where the guy with the 160 IQ beats the guy with a 130 IQ...Give away 30 points to somebody don't need a lot of brains to be in this business."</p><p>A lot of people with crazy high IQs are terrible at this game because they have too many things going on in their heads. What you need is the emotional stability to hone in on a few proven strategies and trade them well.</p><p>In his featured presentation, Matt Choi, CMT will demo a complete options strategy that you can use in today's market.</p><p>This strategy involves:</p><ol><li>Using the Internet as a data-mining tool to find the best stocks to trade</li><li>Applying an options strategy that can generate 100% or higher ROI</li><li>Quickly finding high probability setups week in week out</li></ol><p>And guess doesn't require 160 IQ either.</p>
In this powerful talk, Oliver Velez explains why the entire world is moving to a non-material state. In fact, he shows, with several examples, how this dematerialization has already been taking place over decades. Listen to how vividly Mr. Velez explains why the most valuable things in life will increasingly become things you cannot see, touch, or hold in your hands. Oliver Velez believes this macro view will serve anyone who is looking for the biggest opportunities ahead. Watch, listen, and learn!
Join Simplify Asset Management's Brian Kelleher and Nasdaq's John Black and Carlos Pelaez as they discuss current market themes within the ETF and options space, as well as systematic strategies to hedge risk, such as using defined risk to manage your portfolio.
Against the backdrop of continued tensions in US-China relations, anxiety over a potential taper tantrum, and intensifying inflation fears, what can investors expect for the rest of the year? Our distinguished panel will dissect the economic, global trade, and political landscape and offer a unique perspective on the long- and short-term implications of these factors and more on your portfolio.
Steve O'Loughlin will present Actinium's leadership in the targeted radiotherapy field and how it is the only company pursuing well-validated targets in hematology with late-stage clinical programs. You will learn how the company's Iomab-B and Actimab-A programs have yielded promising clinical data in the relapsed/refractory Acute Myeloid Leukemia (AML). Finally, Mr. O'Loughlin will cover the company's investments in R&D, driving continued innovation in developing Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation.
Covid-19 vaccines have shown the world that biotech is truly a transformative industry. Join Bioinvest's John McCamant to learn how he picks game-changing biotech stocks to super charge your portfolio.
<p>Delta 9 Cannabis' revenue for the 2nd quarter of 2021 was up 29% to $16.75 million, compared with:</p><ul><li>$13.23 million for the first quarter of 2021.</li><li>$13.01 million for the second quarter of 2020.</li><li>Delta 9 revenues for the six-month period ending June 30, 2021, was $30 million up 21%, compared to $24.76 million for the same period last year.</li></ul><p>Delta 9's chief executive officer, John Arbuthnot, was very proud of the company's Q2, 2021 results, with record top-line revenues and a seventh consecutive quarter of positive Adjusted EBITDA. Delta 9 will:</p><ul><li>Continue to grow its brick-and-mortar and online retail business strategy.</li><li>Expand its turnkey Grow Pod sales into the US market with new cultivation partners.</li><li>Continue to lower its cost of production which is currently at $0.65 per gram.</li></ul><p>All three business units contributed to Delta 9's record revenue this quarter. The company anticipates continued growth in all three of its business segments units through the back half of 2021.</p><p>Delta 9 Cannabis placed 7th out of 448 participants on <em>The Globe and Mail's</em> third annual ranking of Canada's top-growing Canadian companies. The survey ranked 448 participants based on three-year revenue growth. Delta 9 Cannabis earned its spot with three-year revenue growth of 5,413%.</p>
reAlpha is revolutionizing the way people invest in real estate and we'd like you to join us as a shareholder. We are democratizing investing through a digital marketplace that enables our members to build wealth through fractional ownership in short-term rental properties.